Courtemanche D J, Worth A J, Coupland R W, MacFarlane J K
Department of Surgery, University of British Columbia, Vancouver.
Can J Surg. 1991 Feb;34(1):15-9.
The monoclonal antibody LICR-LON-M8 was used in a series of experiments to determine how an immunohistochemical technique could be used as a diagnostic test for micrometastatic disease in patients with operable, primary breast carcinoma. Optimal tissue and antigen preservation was obtained with fixatives containing either picric acid or a heavy metal such as mercury to allow staining with the monoclonal antibody diluted to 1:12,000 to 1:16,000 from unpurified mouse ascites. Tissue affected by primary and metastatic disease stains in a characteristic fashion, which is distinct from benign breast tissue. All the ductal tumours stained positively for malignant cells with the monoclonal antibody preparation. Within the bone marrow, occasional granulocytes and granulocyte precursors stained positively if the endogenous peroxidase activity was incompletely blocked. These cells were readily differentiated from tumour cells on cytologic examination. With these monoclonal antibody and immunohistochemical staining techniques it may now be possible to detect early micrometastatic disease in the bone marrow of patients with primary breast cancer.
单克隆抗体LICR-LON-M8被用于一系列实验，以确定免疫组织化学技术如何用作可手术的原发性乳腺癌患者微转移疾病的诊断测试。使用含有苦味酸或重金属（如汞）的固定剂可实现最佳的组织和抗原保存，以便用从未纯化的小鼠腹水中稀释至1:12,000至1:16,000的单克隆抗体进行染色。受原发性和转移性疾病影响的组织以特征性方式染色，这与良性乳腺组织不同。所有导管肿瘤用单克隆抗体制剂对恶性细胞呈阳性染色。在骨髓内，如果内源性过氧化物酶活性未被完全阻断，偶尔的粒细胞和粒细胞前体呈阳性染色。在细胞学检查中，这些细胞很容易与肿瘤细胞区分开来。通过这些单克隆抗体和免疫组织化学染色技术，现在有可能检测原发性乳腺癌患者骨髓中的早期微转移疾病。
